Clinical Trial Update: A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating VX-121 combination therapy in cystic fibrosis patients who are heterozygous for F508del and a minimal function mutation has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-121

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-06-10